Acute Rejection of Renal Transplant Clinical Trial
Official title:
Investigation of the Safety and Immunologic Biomarker After Conversion From Calcineurin Inhibitor to Rapamune in Stable Renal Transplant Recipient
For patients who meet the inclusion criteria and who agree to participate in this study, the investigators sampled peripheral blood 10cc and performed the analysis for immunologic profile just before the conversion of immune suppressant. At 1 month, 6 month, and 1 year from the conversion of Immune suppressant (CNI to rapamune), the investigators performed tha analysis fo immune profile again. During the study period, the interval of the visit of subclinic and the kinds of laboratory test (Blood and urine test) would not change compared to before the start of this study.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04665310 -
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
|
Phase 4 | |
| Completed |
NCT01496703 -
Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients
|
N/A | |
| Completed |
NCT00943228 -
Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation
|
Phase 4 | |
| Recruiting |
NCT05084768 -
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
|
||
| Recruiting |
NCT01513707 -
The Effects of Pre-transplant Dialysis Modality on Post-transplant Events
|
N/A | |
| Not yet recruiting |
NCT02558452 -
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
|
N/A | |
| Not yet recruiting |
NCT05799716 -
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
|
Phase 4 |